Tazeem Akhtar is affiliated with the Department of Nursing at Shifa College of Nursing & Midwifery, part of Shifa Tameer-e-Millat University in Islamabad, Pakistan.

Dr. Mohan, a distinguished physician-scientist, trained in Pathology and Rheumatology at the National University of Singapore and Singapore General Hospital. He completed his doctoral thesis on the cellular immunology of lupus at Tufts University, Boston, and his post-doctoral training focused on the genetic analysis of murine lupus. As an independent investigator, his research has centered on elucidating the cellular, molecular, and genetic factors leading to murine lupus nephritis, with corresponding translational studies in human lupus nephritis. His recent work has focused on translating basic biological findings towards the early diagnosis of end-organ involvement in autoimmune diseases. Currently, Dr. Mohan’s studies utilize proteomic platforms to discover new biomarkers and targets in chronic rheumatic diseases and selected cancers, applying advanced bioengineering technologies to enhance the management of these ailments.

Patrick Honoré, MD, graduated with high distinction from Louvain Medical School (1988) and specialized in Internal Medicine, Intensive Care, and Nephrology. He has trained in ICU abroad (UK, Australia, USA) and is a Board member of the Belgian Intensive Care Society. A prolific author with over 500 papers and 750 abstracts, he has spoken at 750+ conferences worldwide. He leads Critical Care Nephrology platforms, focusing on acute kidney injury, and has held leadership roles at ULB and VUB Universities. Since 2022, he is the Head of ICU at CHU UCL Namur Godinne and Professor at UCL University.

Dr. Muthusamy Thangaraju (Raju) is a breast cancer research scientist. I started my research career as a breast cancer Scientist in 1991 when I was a graduate student at the University of Madras, India. Then I moved to the McGill University, Montreal, Canada as a post-doctoral fellowships and studied the role of protein tyrosine phosphatases, SHP1 and SHP2, in breast cancer growth and progression. Then I joined at the Mayo Clinic, Rochester, MN, and expanded my research in breast cancer and investigated the role of BRCA1 and BRCA2, the two breast cancer susceptibility genes, in the regulation of DNA damage repair and apoptosis in breast cancer. Then I joined the National Cancer Institute (NCI), Frederick, MD where I explored the functional implication of CCAAT/Enhancer Binding Protein delta (CEBPD) in mammary gland development and its relevance to mammary tumor growth and progression. Currently, I am a Professor at the Augusta University and studying the role of epigenetics and regulation of mammary gland development and its association with mammary stem cells (MaSC) and breast cancer stem cell (BCSC) self-renewal. I also studies the role of GPR109A, Netrin-1, and Epigenetics in Autosomal Dominant Polycystic Kidney Disease (ADPKD).